Menu

Eli Lilly headquarters

Eli Lilly has sent multiple covered entities letters stating they must comply with the drugmaker's new 340B in-house pharmacy claims data requirements "without further delay."

Lilly Sends Warning Letters to Providers Over In-House 340B Claims Data Reporting Requirements

May 12, 2026 William Newton, Editor-in-Chief 340B Report Views

Multiple 340B providers have recently received letters from Eli Lilly warning they could lose access to 340B pricing unless they [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

William Newton

Federal Appeals Court Denies Novartis’ Rehearing Request on Mississippi’s 340B Contract Pharmacy Access Law

UCB 7th to Announce In-House Pharmacy Claims Data Requirements, AbbVie Updates States Subject to CP Restrictions